[PDF] Top 20 Diseño de una instalación solar en un hotel para la producción de ACS.
Has 10000 "Diseño de una instalación solar en un hotel para la producción de ACS." found on our website. Below are the top 20 most common "Diseño de una instalación solar en un hotel para la producción de ACS.".
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
... by ipilimumab extends observation of benefits weeks to months after treat- ment ...with ipilimumab. Ipilimumab monotherapy results in four distinct response patterns: (1) shrinkage in baseline ... See full document
47
Cytotoxic T lymphocyte antigen 4 and immune checkpoint blockade
... four-dose treatment period with anti–CTLA-4 antibodies in melanoma (12–16 weeks) and that disease status be confirmed with the same type of imag- ing at least 4 weeks later (51, ... See full document
15
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
... monoclonal antibody which induces long-lasting clinical responses in a minority of patients with metastatic melan- oma ...[16-21]. Ipilimumab with or without a gp100 peptide vaccine, compared with ... See full document
7
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
... anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic ...of T-cell activation. ... See full document
15
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
... with ipilimumab who developed a low FT4 had only a mildly elevated TSH, that was lower than the mean in those with sub-clinical ...with melanoma treated with immune checkpoint ... See full document
71
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma
... humans. Ipilimumab, an anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody, is a new generation immunotherapeutic agent that has shown activity in terms of ... See full document
6
Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets
... a monoclonal antibody directed against IL-12/ 23p40 has the potential to disrupt both Th1 (IL-12) and Th17 (IL-23) ...0, 4, 16) demonstrated that Th1 and Th17 cells each fell by 50%, cytotoxic ... See full document
5
Cardiotoxicity of immune checkpoint inhibitors
... (ie, monoclonal antibodies targeting cytotoxic T lymphocyte- associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligand (PD-L1)) has revolutionised the ... See full document
24
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab
... intracellular antigen exposure after cytotoxic chemotherapy may lead to a better T-cell response and in turn to increased antibody ...in melanoma reported by the Wolchok group is ... See full document
13
Cancer immunotherapy: the beginning of the end of cancer?
... by antigen-stimulated T cells, inhibits T cell proliferation, cytokine release, and cytotoxicity ...hibits T cells and blocks the antitumor immune response after binding to PD-L1 expressed ... See full document
17
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
... Because of her good clinical conditions, the patient was treated with six cycles of chemotherapy with gemci- tabine (1250 mg/m 2 ), on days 1 and 8, plus cisplatin (75 mg/m 2 ) on day 8, every 21 days. In May 2014, ... See full document
5
Trends and advances in tumor immunology and lung cancer immunotherapy
... 2). Treatment- related AEs were low in severity with nivolumab and were less frequent with nivolumab than with ...reported treatment-related AEs of any grade in the nivolumab group were fatigue, nausea, ... See full document
16
The perfect personalized cancer therapy: cancer vaccines against neoantigens
... cancer-specific T-cells by adopt- ing the NCVs approach may lead to a better coverage of ...CD4 T-cells in the periphery by NCVs is likely to result in higher frequency of TILs in patients co- treated with ... See full document
14
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
... metastatic melanoma, which was subsequently validated by Van Allen et ...desmoplastic melanoma, a rare melanoma subtype that has signifi- cantly higher TMB than cutaneous melanomas, Eroglu et ...that ... See full document
10
IMPACT OF CTLA-4 AND NOD2/CARD15 GENE VARIATIONS ON GRAFT- VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT: A STRUCTURED REVIEW
... of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and caspase recruitment domain 15 (NOD2/CARD15) gene polymorphisms on the incidence and severity of aGVHD and cGVHD following ... See full document
14
Dissecting Emerging Aspects of Regulatory Circuitry in Man and Mice: Regulatory T Cell Biology
... pTreg develop extra-thymically when they are exposed to certain regulatory cy- tokines which are released during inflammatory conditions, upon encountering cognate antigens and costimulation [70] [71]. The ... See full document
165
Original Article Relationship between cytotoxic T-lymphocyte antigen 4 (CTLA-4) rs5742909 C>T polymorphism and cancer risk: a meta-analysis based on thirty case-control studies
... [7] Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett ... See full document
401
Management of hypersensivity pneumonitis
... Establishing the diagnosis of HP in the absence of lung biopsy is challenging and is heavily dependent on identification of a specific antigenic exposure. Examination of surgical lung biopsies in HP usually shows an ... See full document
51
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
... Case presentation: This autopsy case illustrates that clinically overt irAEs may represent only a fraction of the total spectrum of immune-related organ pathology in patients treated with immune checkpoint inhibitors. We ... See full document
83
DETECTION OF CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 (CTLA4) IN TYPE 1 DIABETES PATIENTS IN IRAQ BY ELISA
... 12. Momin , S.; Flores, S.; Angel, B.; Codner, D.; Carrasco, P.; Perez- Bravo, E.(2009). Interactions between Programmed death 1 (PD-1) and cytotoxic T lymphoucyte antigen – 4(TLA-4) ... See full document
22
Related subjects